4Q Revenues: $163.4 million (+25%)
4Q Earnings: $3.0 million (loss of $63.4 million 4Q12)
FY Revenues: $575.5 million (+48%)
FY Earnings: $25.0 million (loss of $113.7 million FY12)
Comments: Revenues from the company’s five key commercial products for the quarter grew 26% to $89.5 million. Results reflect the completion of the merger of Alkermes with Elan Drug Technologies (EDT) in Sept. 2011. For the year, revenues included $50.0 million of intellectual property license revenue unrelated to key development programs.